Inventor · disambiguated record

Kevin Fitzgerald

Also filed as: FITZGERALD KEVIN · FITZGERALD KEVIN M

85 granted patents·83 pending applications·912 citations·filing 1994–2025

99Inventor score

Technology areasC12N A61P A61K C12Y G01N

Files withALNYLAM PHARMACEUTICALS INC136 FITZGERALD KEVIN9 ARBUTUS BIOPHARMA CORP2 BETTENCOURT BRIAN2 BRISTOL MYERS SQUIBB CO2

Top patents by PatentIndex Score

168 records

0199US11525138B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2022·Granted Dec 13, 2022·7 cites·28 claims
0299US11130953B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Sep 28, 2021·8 cites·30 claims
0399US7605251B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted Oct 20, 2009·160 cites·20 claims
0498US11866709B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 9, 2024·3 cites·29 claims
0598US11840692B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 12, 2023·3 cites·29 claims
0698US11834662B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Dec 5, 2023·3 cites·29 claims
0798US11332743B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted May 17, 2022·6 cites·26 claims
0898US11306315B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
0998US11306314B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
1098US11306316B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Apr 19, 2022·6 cites·20 claims
1198US9771591B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Sep 26, 2017·22 cites·34 claims
1298US9322018B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 26, 2016·36 cites·41 claims
1398US9249415B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Feb 2, 2016·24 cites·30 claims
1498US9051567B2Methods for increasing efficacy of lipid formulated siRNAFITZGERALD KEVIN·Filed 2010·Granted Jun 9, 2015·104 cites·25 claims
1597US11034958B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Jun 15, 2021·7 cites·17 claims
1697US10851377B2Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorderALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Dec 1, 2020·4 cites·30 claims
1797US10557139B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 11, 2020·15 cites·20 claims
1897US10550390B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Feb 4, 2020·15 cites·20 claims
1997US10337010B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Jul 2, 2019·17 cites·31 claims
2097US9290760B2Modified iRNA agentsRAJEEV KALLANTHOTTATHIL G·Filed 2011·Granted Mar 22, 2016·100 cites·33 claims
2196US11873491B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Jan 16, 2024·2 cites·32 claims
2296US10934545B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Mar 2, 2021·6 cites·25 claims
2396US9850488B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Dec 26, 2017·11 cites·62 claims
2496US9701963B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Jul 11, 2017·9 cites·32 claims
2596US8273869B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2010·Granted Sep 25, 2012·17 cites·27 claims
2695US10570393B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Feb 25, 2020·17 cites·46 claims
2795US9133461B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Sep 15, 2015·19 cites·58 claims
2895US8598139B2Lipid formulated dsRNA targeting the PCSK9 geneFITZGERALD KEVIN·Filed 2012·Granted Dec 3, 2013·15 cites·26 claims
2994US10995336B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted May 4, 2021·8 cites·41 claims
3094US10053689B2Methods for increasing efficacy of lipid formulated siRNAARBUTUS BIOPHARMA CORP·Filed 2015·Granted Aug 21, 2018·7 cites·9 claims
3193US10231988B2Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Mar 19, 2019·10 cites·28 claims
3292US12467051B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2023·Granted Nov 11, 2025·0 cites·13 claims
3392US8222222B2Compositions and methods for inhibiting expression of the PCSK9 geneTAN PAMELA·Filed 2009·Granted Jul 17, 2012·13 cites·27 claims
3492US2025171785A1Compositions and methods for inhibiting expression of the pcsk9 geneALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
3591US11434487B2Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2020·Granted Sep 6, 2022·2 cites·31 claims
3691US11136582B2Ketohexokinase (KHK) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 5, 2021·4 cites·26 claims
3791US10829763B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 10, 2020·4 cites·17 claims
3891US10767177B2Sterol regulatory element binding protein (SREBP) chaperone (SCAP) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Sep 8, 2020·4 cites·59 claims
3990US11198872B2Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Dec 14, 2021·6 cites·33 claims
4090US11162098B2Complement component C5 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Nov 2, 2021·2 cites·19 claims
4190US9631193B2Compositions and methods for inhibiting expression of the ALAS1 geneALNYLAM PHARMACEUTICALS INC·Filed 2013·Granted Apr 25, 2017·8 cites·45 claims
4289US11408001B1Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 9, 2022·1 cites·29 claims
4389US11142766B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2019·Granted Oct 12, 2021·4 cites·21 claims
4489US10407679B2Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Sep 10, 2019·5 cites·43 claims
4589US9260718B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 16, 2016·6 cites·27 claims
4689US8809292B2Compositions and methods for inhibiting expression of the PCSK9 geneTAN PAMELA·Filed 2012·Granted Aug 19, 2014·7 cites·38 claims
4788US11725207B2Serpina1 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2021·Granted Aug 15, 2023·1 cites·123 claims
4888US10246713B2TMPRSS6 iRNA compositions and methods of use thereofALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Apr 2, 2019·6 cites·14 claims
4988US8765932B2Compositions and methods for inhibiting expression of XBP-1 geneFITZGERALD KEVIN·Filed 2012·Granted Jul 1, 2014·4 cites·23 claims
5088US2025034566A1Compositions and methods for inhibiting expression of the alas1 geneALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites

Showing the top 50 of 168 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Kevin Fitzgerald files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →